左西孟旦联合重组人脑利钠肽治疗急性心力衰竭疗效及对NT-proBNP的影响  

Curative effect and influence of levosimendan combined with recombinant human brain natriuretic peptide on acute heart failure and N-terminal pro-brain natriuretic peptide

作　　者：窦旭 黄晓英 杨蕾 王佳 Dou Xu;Huang Xiaoying;Yang Lei;Wang Jia(Department of Emergency,Beijing Puren Hospital,Beijing 100062,China;不详)

机构地区：[1]北京普仁医院急诊内科,北京100062 [2]北京普仁医院心内科,北京100062

出　　处：《中国循证心血管医学杂志》2023年第3期348-351,共4页Chinese Journal of Evidence-Based Cardiovascular Medicine

摘　　要：目的探究左西孟旦联合重组人脑钠肽(rhBNP)治疗急性心力衰竭(急性心衰,AHF疗效及对N末端脑钠肽前体(NT-proBNP)的影响。方法选取2019年2月至2022年2月于北京普仁医院收治的126例急性心衰患者为研究对象,按照随机数字表法分为对照组和观察组,每组各63例,对照组采用左西孟旦治疗,观察组采用左西孟旦联合rhBNP治疗,比较两组疗效、心功能指标、血流动力学、血清乳酸(LA)、NT-proBNP水平及远期预后。结果治疗72 h后,观察组治疗总有效率、心排量指数(CI)、左室射血分数(LVEF)、LA、NT-proBNP水平,中心静脉压(CVP)、平均动脉压(MAP)均高于对照组;左心室舒张末期内径(LVEDD)、左室舒张末期压力(LVEDP)、血清LA、NT-proBNP水平及出院3个月内因心衰再入院率均低于对照组,差异有统计学意义(P<0.05);两组出院6个月内全因死亡率对比,差异无统计学意义(P>0.05)。结论左西孟旦联合rhBNP可显著提高治疗急性心衰的临床疗效,稳定血流动力学,缓解患者心衰症状,改善心功能及远期预后。Objective To discuss the curative effect and influence of levosimendan combined with recombinant human brain natriuretic peptide(rhBNP)on acute heart failure(AHF)and N-terminal pro-brain natriuretic peptide(NT-proBNP).Methods AHF patients(n=126)were chosen from Beijing Puren Hospital from Feb.2019 to Feb.2022,and they were divided,according to random digital table,into control group and observation group(each n=63).The control group was treated with levosimendan,and observation group was treated with levosimendan combined with rhBNP.The curative effect,indexes of heart function,hemodynamics,levels of serum lactic acid(LA)and N-terminal pro-brain natriuretic peptide(NT-proBNP)and long-term prognosis were compared between 2 groups.Results After treatment for 72 h,the total effective rate,cardiac output index(CI),left ventricular ejection fraction(LVEF),LA,NT-proBNP,central venous pressure(CVP)and mean arterial pressure(MAP)were all higher in observation group than those in control group,and left ventricular end-diastolic inner diameter(LVEDD),left ventricular end-diastolic pressure(LVEDP),levels of serum LA and NT-proBNP,and rehospitalization rate due to heart failure within 3 months after discharged were all lower in observation group than those in control group(P<0.05).The difference in all-cause mortality had no statistical significance between 2 groups within 6 months after discharged(P>0.05).Conclusion Levosimendan combined with rhBNP can significantly improve clinical efficacy in AHF treatment,stabilize hemodynamics,effectively alleviate the symptoms of heart failure,and improve heart function and long-term prognosis in AHF patients.

关 键 词：左西孟旦 重组人脑钠肽 急性心力衰竭 疗效 

分 类 号：R541.61[医药卫生—心血管疾病]